NCT02346435Recruiting
The Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry
Source: ClinicalTrials.gov · Last updated 5 Mar 2026
Brief summary (registry, in English)
Retrospective studies indicate that active surveillance for clinically localized, small renal masses (cT1a, \<=4cm) is safe. It is our hypothesis that active surveillance is safe and efficacious when compared prospectively to patients undergoing immediate intervention for their small renal mass.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 600 (estimated)
- First submitted
- 6 Jun 2014
- Start date
- Jan 2009
- Primary completion date
- Jan 2028
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Diseases
- Kidney cancer
- NCT number
- NCT02346435
What you commit to
- Study type: Observational
- Planned participants: 600
- From Jan 2009 to the primary completion date, Jan 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Cannot have suspicion of metastases to the kidney if any other malignancy diagnosed within two years of study entry.
Who the study is looking for
- Must have a solid, enhancing renal mass ≤4cm at its greatest dimension found on incidental scanning in the last 6 months.
- Age ≥ 18 and able to read, understand and sign informed consent.
- Must be willing to adhere to the treatment algorithm and time constraints therein.
Age in the registry: 18 years to 100 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Johns Hopkins Hospital Coordinator of this site? Confirm its status | Baltimore | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.